Preventing malaria relapse with tafenoquine
Part of Infections clinical trials.
This trial tests whether adding the drug tafenoquine to standard malaria treatment can prevent the return of P. vivax malaria. It is for adults who have a normal G6PD enzyme level and are healthy enough to participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have P. vivax malaria (only this type of parasite in your blood).
- Your G6PD enzyme level is normal (a blood test will show this).
- You have a fever (temperature at least 37.5°C) or have had a fever in the last 48 hours.
- You are 18 years of age or older.
- Your hemoglobin level is at least 8 g/dL (a blood test will show this).
- You live in the study area and can commit to follow-up visits for six months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
This trial tests how well the drug primaquine works for people with vivax malaria who have intermediate or low levels of an enzyme called G6PD. It aims to find safe and effective treatment options for this group.
This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
This trial tests whether a shorter course of primaquine can effectively prevent relapses of vivax malaria. It aims to make treatment easier and safer for patients.
This study tests new combinations of antimalarial drugs to better cure P. vivax malaria, a type of malaria parasite. You would receive experimental drug combinations and be monitored for about 6 months to see if they work and are safe.
Hear when a new Vivax Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.